Enduring CME - Personalized Therapies for Breast Cancer

March 11, 2010

Please read the Overview, Learning Objectives, and Faculty Disclosures before you continue to the CME-Accredited Activity. This is an Accreditation Council for Continuing Medical Education (ACCME®) requirement. When you are finished please scroll to the bottom of the Faculty Disclosures page and click the link stating that you have read and understood the faculty disclosures.

CME-Accredited Enduring Materials

All 35 presentations, 8 interactive panel discussions, and 2 Point-Counterpoint debates from the

"First Annual North American Symposium on Personalized Therapies for Breast Cancer"

Miami, FL, January 19-20, 2008

Evaluation & Certificate

Faculty Disclosures

It is the policy of The Oncology Learning Center™, Inc. (OLC) to ensure that all of its educational activities and materials are of the highest quality, and are balanced, objective, independent, free of commercial bias, and planned and developed with scientific rigor with strict adherence to all Accreditation Council for Continuing Medical Education (ACCME) rules and policies. The OLC evaluates all content, faculty and faculty disclosures for any potential conflicts of interest. Should any conflicts of interest be identified these conflicts are resolved in advance of the educational activity by independent peer reviewers who are experts in the subjects of the educational activity.

All faculty and OLC staff participating in the content, planning or implementation of an educational CME activity are required to disclose to the audience of the educational activity any relevant financial relationships or interests and to assist in the resolution of any conflict of interest that may arise from the relationship(s) or interest(s). It is also the policy of the OLC to require all faculty presenters to make a meaningful disclosure to the audience of their discussions of unlabeled or FDA unapproved drugs, products, tests or devices. This information will be available as part of the educational activity and related material.

The following faculty and OLC staff have reported real or potential relevant conflicts of interest and these conflicts have been resolved, prior to this educational activity through a peer-review process by two medical oncologists who have had no affiliation with this educational activity other than the peer review process. This is documented on this page immediately following the financial disclosures below.

Sunil Badve, MD

I have no real or apparent conflicts of interest to report. I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

Donald A. Berry, PhD

Consultant : Abbott, Sanofi-Aventis, Schering-Plough, Astra-Zeneca, Pfizer, Taiho, OSI, Takeda, GlaxoSmithKline, Keryx, Biogen Idec, Eisai, Merck, Eil Lilly, Wyeth, Bristol-Myers Squibb

Chris Brown

I have no real or apparent conflicts of interest to report.

Powel H. Brown, MD, PhD

Consultant: Eli Lilly, Syndax Pharmaceuticals

Grant/Research Support: Astra-Zeneca

Lisa A. Carey, MD

Consultant: Roche, Pfizer, GlaxoSmithKline, Genentech

Contracted Research: BHS, GlaxoSmithKline, Boehringer Ingelheim

Graham A. Colditz, MD, DrPH

I have no real or apparent conflicts of interest to report.

Massimo Cristofanilli, MD

Fees for Non-CME Services Received Directly from Commercial Interest or their Agents: Veride

Ownership Interest: Cellexicon

Francisco J. Esteva, MD, PhD

Fees for Non-CME Services Received Directly from Commercial Interest or their Agents: Genentech

Armando E. Giuliano, MD

I have no real or apparent conflicts of interest to report.

Richard J. Gralla, MD

Consultant: GlaxoSmithKline, Sanofi-Aventis, Merck, MGI Pharma

Grant/Research Support: Sanofi-Aventis

Julie R. Gralow, MD

Consultant: Novartis, Roche, Amgen

Contracted Research: Amgen, Bristol-Myers, Roche, Novartis, GlaxoSmithKline

Ora Guy

I have no real or apparent conflicts of interest to report.

Clifford A. Hudis, MD

Consultant: Amgen, AstraZeneca, Bristol-Myers Squibb Company, Genentech, Lilly , Novartis, Pfizer, Roche, Sanofi-Aventis

Fees for Non-CME Services Received Directly from Commercial Interest or their Agents: AstraZeneca, Genentech, Novartis, Roche

Contracted Research: Kosan

Ownership Interest: Genomic Health

Steve Madison, RPh, MBA

Fees for Market Research & Training: Amgen, Novartis, Prometheus

Catherine MaGill, PhD

Consulting Fees: Proteolix, Translational Oncology, Charles Sholtz (husband), Liquid Agency

Eleftherios P. Mamounas, MD, MPH, FA CS

Consultant: Bristol-Myers Squibb Company, Aventis, Roche, Genentech, Pfizer, GlaxoSmithKline, GHI, Lilly, Novartis

Fees for Non-CME Services Received Directly from Commercial Interest or their Agents: Genentech, GHI, Aventis

Olufunmilayo Olopade, MB, BS

Contracted Research: Roche

Soonmyung Paik, MD

Receipt of Intellectual Property Rights/Patent Holder: Genomic Health Inc.

Consultant: Genentech, GlaxoSmithKline

Mark Pegram, MD

Consultant: Genentech, Inc.

Edith A. Perez, MD

Contracted Research: Genentech, GlaxoSmithKline, Novartis, Sanofi-Avenits

Charles M. Perou, PhD

Consultant: Eli Lilly, Roche, PharmaMar

Contracted Research: Roche, Eli Lilly, BMS

Martine Piccart-Gebhart, MD, PhD

Consultant: Lippincott William & Wilkins, Pfizer

Lori J. Pierce, MD

I have no real or apparent conflicts of interest to report.

Malcolm Pike, MD

I have no real or apparent conflicts of interest to report. I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

Michael Press, MD

Consultant: GlaxoSmithKline, Genentech

Fees for Non-CME Services Received Directly from Commercial Interest or their Agents: Genentech

Contracted Research: GlaxoSmithKline, Genentech

Kathleen I. Pritchard, MD

Consultant: AstraZeneca, Sanofi-Aventis, Roche, Pfizer, Novartis

Lajos Pusztai, MD, DPhil

Consultant: Bristol-Myers Squibb Company, Roche Laboratories, Pfizer

Ownership Interest: Nuvera Biosciences Inc.

Peter M. Ravdin, MD, PhD

Consultant: Sanofi-Aventis

Ownership Interest: Adjuvant Incorporated

Other: Educational Grant � AstraZeneca

Phillip Renner

I have no real or apparent conflicts of interest to report.

Daphne Rhea

I have no real or apparent conflicts of interest to report.

Sandra Roeling

I have no real or apparent conflicts of interest to report.

Dennis J. Slamon, MD, PhD

Fees for Non-CME Services Received Directly from Commercial Interest or their Agents: Genetech

Ownership Interest: Amgen/Schering Plough

George W. Sledge, Jr., MD

Consultant: Genentech, Pfizer

Contracted Research: Eli Lilly, Sanofi-Aventis

Mary Lou Smith

Other Grants: AstraZeneca, Lilly, Genomic Health, Genentech

Joseph Sparano, MD

I have no real or apparent conflicts of interest to report.

Suzette Stewart

I have no real or apparent conflicts of interest to report.

Frank A. Vicini, MD, FA CR

I have no real or apparent conflicts of interest to report.

Jeffrey N. Weitzel, MD

I have no real or apparent conflicts of interest to report.

Eric P. Winer, MD

I have no real or apparent conflicts of interest to report.

Faculty Affiliations

Sunil Badve, MD Associate Professor of Pathology Clarian Pathology Laboratory Indiana University Cancer Center		Charles M. Perou, PhD Associate Professor Department of Genetics University of North Carolina At Chapel Hill
Donald A. Berry, MD, PhD Head, Division of Quantitative Sciences Professor and Frank T. McGraw Memorial Chair for Cancer Research Chairman, Department of Biostatistics MD Anderson Cancer Center		Martine Piccart-Gebhart, MD, PhD Head of the Chemotherapy Department Jules Bordet Institute President, European Organization for the Research and Treatment of Cancer (EORTC)
Powel H. Brown, MD, PhD Professor of Medicine, Baylor College of Medicine Associate Director of Cancer Prevention, Dan L. Duncan Cancer Center Director of Cancer Prevention and Population Sciences Program, Dan L. Duncan Cancer Center Associate Director of Research, Breast Center Baylor College of Medicine		Lori J. Pierce, MD Vice Provost for Academic and Faculty Affairs Professor, Department of Radiation Oncology University of Michigan
Lisa A. Carey, MD Medical Director, UNC Breast Center University of North Carolina - Lineberger Comprehensive Cancer Center		Malcolm Pike, MD Professor and Acting Chair, Flora L. Thornton Professor USC Norris Cancer Center
Graham A. Colditz, MD, DrPH Niess-Gain Professor in the School of Medicine Department of Surgery Associate Director Prevention and Control Alvin J. Siteman Cancer Center Washington University School of Medicine		Michael F. Press, MD, PhD Harold E. Lee Chair in Cancer Research Professor, Pathology USC/Norris Comprehensive Cancer Center
Massimo Cristofanilli, MD Associate Professor, Breast Medical Oncology MD Anderson Cancer Center		Kathleen I. Pritchard, MD Chair of the Breast Cancer Site Group Toronto-Sunnybrook Regional Cancer Center
Francisco J. Esteva, MD, PhD Associate Professor of Medicine Department of Breast Medical Oncology Department of Molecular and Cellular Oncology MD Anderson Cancer Center, University of Texas		Lajos Pusztai, MD, DPhil Associate Professor of Medicine Department of Breast Medical Oncology MD Anderson Cancer Center
Armando E. Giuliano, MD Chief of Science and Medicine Breast and Endocrine Program John Wayne Cancer Institute		Peter Ravdin, MD Research Professor, Department of Biostatistics MD Anderson Cancer Center
Richard J. Gralla, MD President, Multinational Association of Supportive Care in Cancer (MASCC) Past President and Current Board Member, New York Lung Cancer Alliance New York, NY		Dennis J. Slamon, MD, PhD Chief, Division of Hematology-Oncology Professor and Executive Vice Chair, Department of Medicine Director for Clinical Research Jonsson Comprehensive Cancer Center Director, Revlon/UCLA Women’s Health Research and Cancer Research Programs University of California at Los Angeles School of Medicine Los Angeles, California
Julie R. Gralow, MD Associate Professor of Medical Oncology University of Washington School of Medicine Cancer Care Alliance Seattle, WA Co-Chair, Breast Committee, The Southwest Oncology Group (SWOG)		George Sledge, Jr., MD Ballve-Lantero Professor of Oncology Co-Director, Breast Cancer Program Indiana University Cancer Center Indianapolis, IN Co-Chair, Breast Committee, The Eastern Oncology Cooperative Group (ECOG)
Clifford A. Hudis, MD Chief, Breast Cancer Medicine Service Memorial Sloan-Kettering Cancer Center New York, NY Co-Chair, Breast Committee, The Cancer and Leukemia Group B (CALGB)		Mary Lou Smith Co-chair of the ECOG Patient Representative Committee Co-Founder Research Advocacy Network
Eleftherios P. Mamounas, MD, MPH, FA CS Associate Professor of Surgery Cancer Center, Aultman Health Foundation Northeastern Ohio Universities College of Medicine		Joseph A. Sparano, MD Professor of Medicine, Albert Einstein College of Medicine, Director, Breast Evaluation Center, Montefiore-Einstein Cancer Center
Olufunmilayo Olopade, MB, BS Walter L. Palmer Distinguished Service Professor in Medicine and Human Genetics Director, Hematology/Oncology University of Chicago		Frank A. Vicini, MD Chief of Oncology Service Program Director, Radiation Oncology William Beaumont Hospital
Soonmyung Paik, MD Director, Division of Pathology NSABP Foundation		Jeffrey N. Weitzel, MD Professor of Oncology and Population Sciences Director, Department of Clinical Cancer Genetics City of Hope Cancer Center
Mark Pegram, MD Associate Professor of Medicine University of Miami		Eric P. Winer, MD Director, Breast Oncology Center Thompson Investigator in Breast Cancer Research Department of Medical Oncology Dana-Farber Cancer Institute / Harvard Cancer Center Boston, MA Co-Chair, Breast Committee, The Cancer and Leukemia Group B (CALGB)
Edith A. Perez, MD Professor of Medicine Director, Clinical Research, Mayo Clinic Jacksonville, FL Chair, Breast Committee, The North Central Cancer Treatment Group (NCCTG)

Peer Review Process of Conflicts of Interest

Drs. Jennifer Ligibel of the Dana Farber Cancer Institute, Boston, MA, and Patrick J. Flynn of US Oncology in Minneapolis, MN. Have independently peer-reviewed this enduring material educational activity.

Note: To enlarge the COI form image, please click on it.

Disclosure of Unlabeled Uses

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product or consult the Physicians’ Desk Reference.

The Oncology Learning Center (OLC) does not recommend the use of any agent outside of the FDA labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the OLC. Please refer to the official FDA prescribing information for each product for discussion of approved indicated, contraindications, and warnings.

Acknowledgement of Supporters

Educational Grants
Sincere appreciation is extended to the following companies for their generous support of this educational meeting: Genentech BioOncology, Novartis, Bristol-Myers Squibb, Lilly, Abraxis BioScience, AstraZeneca, Genomic Health, Eisai, sanofi-aventis, Bayer, Onyx, AviaraDx, Abbott

1415 Legacy Drive, Suite 250 • Frisco, TX 75034 • Phone: 214.866.0305 • Fax: 214.866.0311

Disclaimer: The material published on the Oncology Learning Center Web site reflect the opinions and expertise of the authors and/or reviewers of the material, and not the opinions of the Oncology Learning Center, the CME provider, or the pharmaceutical companies providing educational grants. The materials may address uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. Before using any therapeutic approaches reviewed in this material, a qualified medical or surgical oncologist, or hematologist should be consulted. Readers of this content should verify all information and data before treating patients or using any drugs or therapies described in any Oncology Learning Center materials. Click here for our Privacy Policy.